Evidence map›Paper›PMID 41191153›Full record

SynthesisNeurosurgical review2025

Stereotactic radiosurgery (SRS) for primary spinal bone tumors: a systematic review and meta-analysis.

Emil O R Nordin, Vivek Sanker, Philip Heesen, Aaditya Dravid, Srinath Hariharan, Olga Ciobanu-Caraus, Maria Jose Cavagnaro, Ikchan Jeon, David Park, Steven Chang and 2 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emil O R NordinDepartment of Neurosurgery, Stanford University, Stanford, CA, USA. enordin@stanford.edu.
Vivek SankerDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
Philip HeesenUniversity of Zurich, Zurich, Switzerland.
Aaditya DravidImperial College London School of Medicine, London, UK.
Srinath HariharanDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
Olga Ciobanu-CarausDepartment of Neurosurgery, LMU University Hospital, LMU Munich, Munich, Germany.
Maria Jose CavagnaroDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
Ikchan JeonDepartment of Neurosurgery, Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, South Korea.
David ParkDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
Steven ChangDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
John K RatliffDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
Atman DesaiDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While surgery is a vital component in the treatment of most primary spinal bone tumors (PSBTs), it is only one aspect of a comprehensive management plan. Optimizing patient outcomes often requires a multidisciplinary approach, incorporating medical oncology and interventional radiology. The use of stereotactic radiosurgery (SRS) is typically considered when patients are either poor surgical candidates or have recurrent or unresectable tumors. However, the use of SRS and its efficacy remains relatively unclear. Our aim with this study is to investigate the therapeutic response among PSBTs treated with SRS. We performed a systematic literature search in the databases Medline, Embase (Ovid), Scopus, Web of Science Advance and Cochrane Central from inception to July 8, 2024. We included studies that reported on outcomes of SRS in patients with PSBTs and meta-analyzed the proportions of recurrence, progression, and local control (LC). The quality of included studies was assessed using the MINORS tool for non-randomized studies. We identified 5 studies with relevant data for our meta-analysis, and our results consist of overall analyses that compile all the relevant data, and a subgroup analysis for chordomas. The compiled pooled proportion of LC was 0.81 [95% CI: 0.55; 0.94], and in the chordoma subgroup, it was 0.82 [95% CI: 0.59; 0.93]. The compiled pooled proportion of recurrence was 0.14 [95% CI: 0.03; 0.47], and in the chordoma subgroup, it was 0.14 [95% CI: 0.03: 0.47]. The compiled pooled proportion of progression was 0.26 [0.15; 0.42], and in the chordoma subgroup, it was 0.22 [95% CI: 0.10; 0.41]. Our meta-analysis suggests that treating PSBTs with SRS is associated with promising results in terms of LC (81%), but 14% of the cases had recurrence, and 26% showed tumor progression. Thus, SRS as a primary treatment modality for PSBTs still requires further modifications to further enhance results and improve patient outcomes.

Indexed as

ChordomaRadiosurgerySpinal NeoplasmsHumansNeoplasm Recurrence, LocalTreatment OutcomeSacral chordomaSarcomaSpine tumorStereotactic radiosurgery

Identifiers

PMID41191153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.